A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma

Summary

The goal of this investigator-initiated, a single-arm, open-label, pilot study is to investigate the safety, tolerability, and efficacy of CD-801 treatment in subjects with advanced hepatocellular carcinoma. Condition of disease: advanced hepatocellular carcinoma . Intervention：treatment with 100μg CD-801 through the hepatic artery at two-week intervals. The dosing interval will be adjusted based on subject tolerability, safety, and efficacy. For example, it may be adjusted to administer the medication once every three weeks or four weeks. Drug: CD-801, a drug designed specifically to enhance the expression of HNF4α and selectively target liver cancer cells.

Timeline

Start

2023-10-13

Primary completion

2024-04-29

Completion

2024-04-29

Drugs

Indications